Hemodynamic Effects of Rauwolfia Alkaloid (Reserpine) in Human Pregnancy. Results of Intravenous Administration**This investigation was supported (in part) by Grant H-1755 from the National Heart Institute, National Institutes of Health and (in part) by a grant from Ciba Pharmaceutical Products, Inc., Summit, N. J.
Authors:
- 1 February 1956
- journal article
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 71 (2) , 237-246
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- CARDIOVASCULAR AND RENAL HEMODYNAMIC RESPONSE TO RESERPINE (SERPASIL), AND CLINICAL RESULTS OF USING THIS AGENT FOR THE TREATMENT OF HYPERTENSIONAnnals of the New York Academy of Sciences, 1954
- ENDOCRINE ASPECTS OF THE PHARMACOLOGY OF RESERPINEAnnals of the New York Academy of Sciences, 1954
- PHARMACOLOGY OF RAUWOLFIA ALKALOIDS, INCLUDING RESERPINEAnnals of the New York Academy of Sciences, 1954
- INTRAVENOUS RESERPINE IN PATIENTS WITH ESSENTIAL HYPERTENSIONAnnals of the New York Academy of Sciences, 1954
- CLINICAL AND EXPERIMENTAL EFFECTS OF RESERPINE IN PATIENTS WITH ESSENTIAL HYPERTENSIONAnnals of the New York Academy of Sciences, 1954
- CLINICAL USAGE OF RAUWOLFIA ALKALOIDS, INCLUDING RESERPINE (SERPASIL)Annals of the New York Academy of Sciences, 1954
- The Medical Management of Arterial HypertensionNew England Journal of Medicine, 1953
- The Use ofRauwolif serpentinain Hypertensive PatientsNew England Journal of Medicine, 1953
- Reserpin, der sedative Wirkstoff ausRauwolfia serpentina BenthCellular and Molecular Life Sciences, 1952
- A CLINICAL TRIAL OF RAUWOLFIA SERPENTINA IN ESSENTIAL HYPERTENSIONHeart, 1949